Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Cold Tumors: A Therapeutic Challenge for Immunotherapy.

Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, Caux C, Depil S.

Front Immunol. 2019 Feb 8;10:168. doi: 10.3389/fimmu.2019.00168. eCollection 2019. Review.

2.

Pattern recognition receptors: immune targets to enhance cancer immunotherapy.

Shekarian T, Valsesia-Wittmann S, Brody J, Michallet MC, Depil S, Caux C, Marabelle A.

Ann Oncol. 2017 Aug 1;28(8):1756-1766. doi: 10.1093/annonc/mdx179. Review.

PMID:
28444111
3.

Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues.

Bardo-Brouard P, Vieillard V, Shekarian T, Marabelle A, Astier A, Paul M.

Eur J Cancer. 2016 May;58:8-16. doi: 10.1016/j.ejca.2016.01.008. Epub 2016 Feb 23.

PMID:
26922168
4.

Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.

Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vély F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, Perri P, Tchirkov A, Matta J, Lapierre V, Shekarian T, Valsesia-Wittmann S, Commo F, Prada N, Poirier-Colame V, Bressac B, Cotteret S, Brugieres L, Farace F, Chaput N, Kroemer G, Valteau-Couanet D, Zitvogel L.

Sci Transl Med. 2015 Apr 15;7(283):283ra55. doi: 10.1126/scitranslmed.aaa2327.

PMID:
25877893
5.

Paradigm shift in oncology: targeting the immune system rather than cancer cells.

Shekarian T, Valsesia-Wittmann S, Caux C, Marabelle A.

Mutagenesis. 2015 Mar;30(2):205-11. doi: 10.1093/mutage/geu073. Review.

PMID:
25688113

Supplemental Content

Loading ...
Support Center